Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Original Investigation titled “Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible And Ineligible Patients in BADBIR,”1 published online March 28, 2018, there was information omitted regarding study funding. Support from the Department of Health via the NIHR BioResource Clinical Research Facility and comprehensive Biomedical Research Centre award to Guy’s and St Thomas’ NHS Foundation Trust in partnership with King’s College London and King’s College Hospital NHS Foundation Trust has now been correctly acknowledged. This article was corrected online.
Missing Information About Study Funding. JAMA Dermatol. 2018;154(7):852. doi:10.1001/jamadermatol.2018.2319
Coronavirus Resource Center